Interleukin-2 (IL-2) augments host cellular immune reactivity in the perioperative period in patients with malignant disease

David J. Deehan*, Steven D. Heys, Julian Ashby, Oleg Eremin

*Corresponding author for this work

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Major surgery impairs cellular and humoral immunity, in particular natural cytotoxicity, and this may facilitate the dissemination of tumour cells in the peri-operative period. Recombinant interleukin-2 (rIL-2) has been used to modulate peri-operative immune function. Eighteen patients were randomized to receive either rIL-2 or placebo for three days, as a subcutaneous injection, prior to surgical resection for colorectal cancer. Natural cytotoxicity (natural killer (NK) and lymphokine-activated killer (LAK) cell activity), monocyte phagocytosis and immune cell surface activation marker (CD14+HLA-DR) expression were assessed during therapy and for up to 21 days after surgery. rIL-2 therapy enhanced both NK and LAK cell-mediated cytotoxicity and augmented circulating lymphocyte CD16+ and CD56+ cell subset populations. Circulating monocyte phagocytosis was also increased. Hence, rIL-2 may be used to enhance immune function in the peri-operative period in patients undergoing curative cancer surgery.

Original languageEnglish
Pages (from-to)16-22
Number of pages7
JournalEuropean Journal of Surgical Oncology
Volume21
Issue number1
DOIs
Publication statusPublished - 1 Feb 1995

Keywords

  • immunosuppression
  • interleukin-2
  • natural cytotoxicity

Fingerprint Dive into the research topics of 'Interleukin-2 (IL-2) augments host cellular immune reactivity in the perioperative period in patients with malignant disease'. Together they form a unique fingerprint.

  • Cite this